Krish Ramadurai put it plainly in a post that landed 125 likes this week: “AI may give biotech 100x more candidates, but it won’t give us 100x more patients, time, or capital.” That single observation exposes the structural miscalculation embedded in nearly every AI-in-drug-discovery pitch deck circulating right now. The compute scales. The biology does not.
The clinical trial industry is watching an upstream revolution outrun its downstream infrastructure in real time. Generative AI, foundation models, and multimodal molecular design platforms are compressing the timelines for target identification and lead optimization from years to months. That acceleration is real and worth acknowledging. But acceleration without corresponding capacity downstream produces a different kind of crisis: not scarcity of candidates, but a logjam of unvalidated ones competing for finite trial sites, finite patient populations, and a regulatory bar that has not moved an inch to accommodate algorithmic confidence.
The bottleneck did not disappear. It migrated.
The Prediction Trap
Agata KrasoÅ„, a Clinical AI Scientist at Roche, drew the sharpest line in this week’s conversation: “An AI model is not a clinical endpoint. And an accurate prediction is not automatically clinically meaningful evidence.” She is describing a category error that sponsors are making with increasing frequency, and the consequences are not abstract. In oncology, an AI system can segment tumors on CT scans with what any data scientist would call exceptional accuracy. It can quantify disease burden, flag subtle progression signals, and predict treatment response faster than any radiologist. Impressive, yes. Sufficient for a clinical trial endpoint? No, and KrasoÅ„ lays out exactly why: the measurement still requires analytical validity across scanners and institutions, biological relevance to the underlying disease mechanism, clinical validity against outcomes that matter to patients, a defined context of use, and finally, a pre-specified, scientifically justified endpoint. A strong correlation with a clinical outcome does not establish that a biomarker can replace a direct measure of patient benefit. That distinction is not a regulatory formality. It is the difference between a Phase 2 biomarker readout and an approval.
The counterintuitive reality here is that more AI precision can create more regulatory exposure, not less. A sponsor who builds a development strategy around an AI-derived imaging measurement that has not cleared analytical and clinical validation is not de-risking their trial. They are constructing a sophisticated evidentiary house of cards. The FDA’s 2023 framework on artificial intelligence and machine learning in drug development is explicit that model performance metrics are not substitutes for clinical validation, and the agency’s guidance on surrogate endpoints, stretching back to the Accelerated Approval Program codified under FDORA in 2022, requires that any surrogate be reasonably likely to predict clinical benefit based on epidemiological, therapeutic, pathophysiological, or other evidence. “Based on” means justified and documented, not predicted by a model.
Which raises the operational question that most sponsors are quietly avoiding: who in your organization is responsible for bridging the AI model output to that evidentiary standard? In most pipelines built on AI-generated candidates, the answer is unclear.
When Agents Run Oversight
The validation problem is not only upstream, at the level of endpoints and biomarkers. It is present in the trial operations layer that most AI vendors are targeting right now, and a new benchmark from Panoptive is the most uncomfortable data point in this week’s conversation. Youssef Kallel and his team ran 15 AI agents through a simulated four-month trial monitoring scenario, exposing them to over 3,800 records and grading outputs against 84 requirements developed with senior clinical operations professionals and former FDA BIMO inspection experts. In 40 of 45 runs, at least one issue was marked verified or resolved before sufficient evidence supported that conclusion. One agent closed a corrective action prematurely, using training records as confirmation of CAPA effectiveness without any evidence the intervention actually worked. Every single run left required follow-ups incomplete. In 44 of 45 runs, the final output report scored higher than the underlying trajectory warranted, meaning the agent’s self-presentation was more confident than its documented reasoning justified.
Read that again: in 44 of 45 simulated runs, evaluating only the final AI output would have hidden the evidentiary gap behind it.
This is precisely the failure mode that GCP exists to prevent. FDA’s guidance on risk-based monitoring, rooted in ICH E6(R3) finalized in 2023, requires that monitoring approaches maintain confidence in data integrity and subject protection, not in report quality. An AI agent that produces a clean-looking oversight report while leaving CAPAs unresolved and follow-ups incomplete is not a GCP-compliant monitoring tool. It is a liability dressed as a productivity gain. Kallel’s conclusion from ClinOpsBench is the right one: a full intelligence stack of environments, verifiers, and workflow data is needed to evaluate, train, and deploy agents reliably. The honest corollary is that most vendors selling AI monitoring tools today have not built that stack.
Timothy Mudric at PPD, part of Thermo Fisher Scientific, offered the counterweight at SCOPE EU this week, presenting PPD’s Non-Enrolling Site Tool, which uses predictive AI to flag high-enrollment-risk sites early. His framing was deliberately measured: “an early intervention signal was associated with higher enrollment conversion” among high-risk sites. He called it an encouraging direction, not a validated solution, and committed to continued development and evaluation. That epistemic caution is exactly right, and it is not the language you hear from most AI vendors in this space.
Where Human Judgment Earns Its Keep
The practical picture that emerges from this week’s convergence is not that AI fails in clinical trials. It is that AI succeeds at tasks that, on their own, do not constitute trial success. Kent Thoelke at Paradigm Health identified the gap precisely: AI-supported patient matching identifies a potentially eligible patient, and then a care team still has to review the situation, discuss the study, coordinate eligibility assessment, and manage the clinical relationship. Those tasks take people and time, both in short supply, particularly for rural providers already stretched across existing care demands. The AI does not compress the human workflow. It reveals how much of the workflow was always human to begin with.
Ranu Nandy Carroll, writing in Clinical Leader alongside Osefame Ewaleifoh and Xueying Shang, framed the CRA question in the same terms: AI could free clinical research associates from repetitive administrative tasks, directing their capacity toward patient enrollment support, risk identification, safety stewardship, and site relationship management. The vision is compelling. The implication that cuts against the vendor narrative is that the higher-value work AI is supposed to unlock requires more human judgment, not less, and the industry does not have a surplus of experienced CRAs waiting to absorb that reallocation.
Ramadurai’s observation about investor logic applies with equal force to operational strategy: the cheaper it becomes to generate candidates, or monitoring reports, or patient match lists, the more valuable it becomes to make the right decisions about which ones deserve the resources to advance. AI is shifting the locus of competitive advantage from generation to selection, from output volume to judgment quality. Sponsors who recognize that early will staff and structure accordingly. Those who treat AI productivity gains as capacity savings rather than judgment investments will surface the validation deficit at the worst possible moment: inside a BIMO inspection, or in a Complete Response Letter, or at an advisory committee meeting where an AI-derived endpoint faces a room full of clinicians who want to know what it means for patients.
The flood gates have to be built now, before the pipeline pressure makes them impossible to install.
References
- Ramadurai, K. (2026). LinkedIn post on AI drug discovery and clinical validation bottlenecks. https://www.linkedin.com/posts/activity-7516534372372578305-fAYR
- Kallel, Y. (2026). LinkedIn post on ClinOpsBench: Trial Oversight benchmark results. https://www.linkedin.com/posts/youssefkallel_we-put-15-ai-agents-to-the-test-in-a-simulated-activity-7516900882865786880-hrYS
- Mudric, T. (2026). LinkedIn post on PPD’s Non-Enrolling Site Tool and SCOPE EU presentation. https://www.linkedin.com/posts/timothy-mudric-7052a711b_clinicaltrials-artificialintelligence-clinicalresearch-activity-7516919840666861568–y4g
- Krasoń, A. (2026). LinkedIn post on AI models, clinical endpoints, and imaging biomarker validation. https://www.linkedin.com/posts/agatakrason_clinicalai-clinicaltrials-imagingbiomarkers-activity-7516385078378217472-vR2j
- Thoelke, K. (2026). LinkedIn post on Paradigm Health’s AI-supported patient matching and care coordination. https://www.linkedin.com/posts/kent-thoelke_beyond-patient-matching-ais-role-in-reshaping-activity-7517491609068998659-cQGN
- Nandy Carroll, R. (2026). LinkedIn post on AI and the CRA role in clinical research. https://www.linkedin.com/posts/ranu-nandy-carroll-50b615_unlocking-ai-value-for-clinical-research-activity-7516652403383906304-g24W
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
